Vertex Inc. (VERX)
What Makes Vertex (VERX) a Strong Momentum Stock: Buy Now?
Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vertex: Downgrading To A Hold As Upside Is Limited
Downgrading Vertex to neutral due to limited upside at current valuation of 10x FY25 revenue, despite robust growth outlook and strong performance. 3Q24 results exceeded expectations with $170M revenue, driven by 21% y/y subscription growth and 270 bps gross margin expansion. VERX's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle, with significant opportunities ahead.
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex, Inc. (VERX) Q3 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Joe Crivelli - Vice President, Investor Relations David DeStefano - President & Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham Steve Enders - Citi Chris Quintero - Morgan Stanley Alex Sklar - Raymond James Daniel Jester - BMO Capital Markets Samad Samana - Jefferies Jake Roberge - William Blair Rob Oliver - Baird Adam Hotchkiss - Goldman Sachs Brad Reback - Stifel Natalie Howe - Bank of America Patrick Walravens - Citizens JMP Securities Operator Good day, and welcome to the Vertex Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Vertex (VERX) Q3 Earnings and Revenues Surpass Estimates
Vertex (VERX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.10 per share a year ago.
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in the background to get treatment centers up and running and patients treated. The VX-880 clinical program is progressing to the pivotal stage and povetacicept generated promising data in membranous nephropathy patients.
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Vertex Pharmaceuticals beat third-quarter expectations on Monday. Though the company raised its sales outlook, Vertex stock was muted.
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Its latest report of clinical data suggests it has a winner on its hands.
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown great potential, and their recent M&A activity has proven they can invest intelligently in order to create shareholder value. While the value of their shares has appreciated over 100% over the last 24 months, the company remains fairly valued due to their reliable recurring CF-treatment revenue and robust pipeline.
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment process and high costs, alongside competition from Bluebird Bio, make the launch challenging. Suzetrigine's potential in chronic pain, a large market with significant unmet needs, could drive substantial revenue if clinical data is positive.
